(Q45399839)

14 December 2017

Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma (English)

1 reference

14 December 2017

1 reference

1 reference

1 reference

3

Takashi Kumada

1 reference

14 December 2017

4

Hidenori Toyoda

1 reference

14 December 2017

8

Masatoshi Ishigami

1 reference

14 December 2017

11

Hidemi Goto

1 reference

14 December 2017

2

Yoshiaki Katano

1 reference

14 December 2017

1

Teiji Kuzuya

1 reference

14 December 2017

6

Yoshiki Hirooka

1 reference

14 December 2017

7

Akihiro Itoh

1 reference

14 December 2017

5

Isao Nakano

1 reference

14 December 2017

Kazuhiko Hayashi

9

1 reference

PubMed ID

17914972

14 December 2017

Takashi Honda

series ordinal

10

1 reference

14 December 2017

1 November 2007

1 reference

Journal of Gastroenterology and Hepatology

14 December 2017

1 reference

14 December 2017

22

1 reference

14 December 2017

1929-1935

1 reference

14 December 2017

11

1 reference

Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV.

14 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Prevention of hepatitis B virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04707.X

10.1111/J.1440-1746.2006.04707.X

21 January 2018

Identifiers

DOI

1 reference

14 December 2017

1 reference

PubMed ID

17914972